These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 15035873)

  • 21. Growth characteristics of renal cortical tumors in patients managed by watchful waiting.
    Sowery RD; Siemens DR
    Can J Urol; 2004 Oct; 11(5):2407-10. PubMed ID: 15579229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The optimize project: beyond first-line therapy in metastatic renal cell carcinoma.
    Castellano D; Bellmunt J
    Cancer Metastasis Rev; 2012 Sep; 31 Suppl 1():S1-2. PubMed ID: 22767406
    [No Abstract]   [Full Text] [Related]  

  • 23. Renal cell carcinoma with tumor thrombus extension into the vena cava: prospective long-term followup.
    Haferkamp A; Bastian PJ; Jakobi H; Pritsch M; Pfitzenmaier J; Albers P; Hallscheidt P; Müller SC; Hohenfellner M
    J Urol; 2007 May; 177(5):1703-8. PubMed ID: 17437789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Observation should be considered as an alternative in management of renal masses in older and comorbid patients.
    Beisland C; Hjelle KM; Reisaeter LA; Bostad L
    Eur Urol; 2009 Jun; 55(6):1419-27. PubMed ID: 19147267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Renal sinus fat invasion in pT3a clear cell renal cell carcinoma affects outcomes of patients without nodal involvement or distant metastases.
    Bertini R; Roscigno M; Freschi M; Strada E; Petralia G; Pasta A; Matloob R; Sozzi F; Da Pozzo L; Colombo R; Guazzoni G; Doglioni C; Montorsi F; Rigatti P
    J Urol; 2009 May; 181(5):2027-32. PubMed ID: 19286201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of renal masses in patients medically unsuitable for nephrectomy--natural history, complications, and outcome.
    Lamb GW; Bromwich EJ; Vasey P; Aitchison M
    Urology; 2004 Nov; 64(5):909-13. PubMed ID: 15533476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity.
    Massenkeil G; Roigas J; Nagy M; Wille A; Stroszczynski C; Mapara MY; Loening S; Dörken B; Arnold R
    Bone Marrow Transplant; 2004 Aug; 34(4):309-16. PubMed ID: 15220955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal cell carcinoma presenting with vaginal metastasis.
    Griffin SJ; Loftus B; McDermott TE; Grainger R
    Ir Med J; 2003 Apr; 96(4):115-6. PubMed ID: 12793475
    [No Abstract]   [Full Text] [Related]  

  • 29. The role of molecular markers in the staging of renal cell carcinoma.
    Leppert JT; Pantuck AJ; Figlin RA; Belldegrun AS
    BJU Int; 2007 May; 99(5 Pt B):1208-11. PubMed ID: 17441912
    [No Abstract]   [Full Text] [Related]  

  • 30. Update on staging controversies for locally advanced renal cell carcinoma.
    Margulis V; Wood CG
    Expert Rev Anticancer Ther; 2007 Jul; 7(7):909-14. PubMed ID: 17627450
    [No Abstract]   [Full Text] [Related]  

  • 31. Proceedings of UICC International Symposium on the Status of Treatment of Metastatic Renal Cell Carcinoma. Vienna, Austria: Part II.
    Semin Surg Oncol; 1988; 4(3):149-209. PubMed ID: 3187292
    [No Abstract]   [Full Text] [Related]  

  • 32. Prognostic factors for renal cell carcinoma with tumor thrombus extension.
    Klatte T; Pantuck AJ; Riggs SB; Kleid MD; Shuch B; Zomorodian N; Kabbinavar FF; Belldegrun AS
    J Urol; 2007 Oct; 178(4 Pt 1):1189-95; discussion 1195. PubMed ID: 17698087
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The potential of virus-based gene therapies for treatment of metastatic kidney cancer.
    Dent P; Curiel DT; Fisher PB
    Expert Rev Anticancer Ther; 2011 Jun; 11(6):809-11. PubMed ID: 21707273
    [No Abstract]   [Full Text] [Related]  

  • 34. Renal cell carcinoma: current status and emerging therapies.
    Nelson EC; Evans CP; Lara PN
    Cancer Treat Rev; 2007 May; 33(3):299-313. PubMed ID: 17329029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunotherapy for metastatic renal cell carcinoma: a review.
    Debruyne FM; de Mulder PH
    Prog Clin Biol Res; 1989; 303():621-7. PubMed ID: 2675016
    [No Abstract]   [Full Text] [Related]  

  • 36. Choroidal and conjunctival metastases from renal cell carcinoma.
    Rodney AJ; Gombos DS; Fuller GN; Pagliaro LC; Tannir NM
    Am J Clin Oncol; 2009 Aug; 32(4):448-9. PubMed ID: 19657240
    [No Abstract]   [Full Text] [Related]  

  • 37. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
    Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
    Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New treatments for metastatic kidney cancer.
    Mancuso A; Sternberg CN
    Can J Urol; 2005 Feb; 12 Suppl 1():66-70; discussion 105. PubMed ID: 15780170
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal cell carcinoma: urologists in a new era.
    Uzzo RG
    J Urol; 2005 Nov; 174(5):1723-4. PubMed ID: 16217270
    [No Abstract]   [Full Text] [Related]  

  • 40. [Case of sarcomatoid renal cell carcinoma developed in the chalked kidney (putty kidney)].
    Komeya M; Sano F; Kagota M; Murakami T; Makiyama K; Miyoshi Y; Nakaigawa N; Ogawa T; Uemura H; Yao M; Ooshiro H; Nagashima Y; Kubota Y
    Hinyokika Kiyo; 2009 May; 55(5):253-7. PubMed ID: 19507542
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.